Topics

TOCA 511 and Toca FC Treatment Misses OS Endpoint in Glioma Trial

11:42 EDT 13 Sep 2019 | OncLive

Treatment with Toca 511 and Toca FC did not improve overall survival compared with standard therapy in patients with recurrent high-grade glioma undergoing resection, missing the primary endpoint of the phase III Toca 5 trial.

Original Article: TOCA 511 and Toca FC Treatment Misses OS Endpoint in Glioma Trial

NEXT ARTICLE

More From BioPortfolio on "TOCA 511 and Toca FC Treatment Misses OS Endpoint in Glioma Trial"

Quick Search

Relevant Topic

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...